Symptom experience after discontinuing use of estrogen plus progestin. - Wikidata - wikimedia - TriplyDB

Symptom experience after discontinuing use of estrogen plus progestin.

Symptom experience after discontinuing use of estrogen plus progestin.

http://www.wikidata.org/entity/Q34433581

about

Progesterone exerts neuroprotective effects after brain injury Estrogen and progestogen use in postmenopausal women: July 2008 position statement of The North American Menopause Society.Menopausal hormone therapy and breast cancer mortality: clinical implications Advances in the treatment of menopausal symptoms.Factors associated with successful discontinuation of hormone therapy.Caring for the breast cancer survivor's health and well-being.Long-term effects of conjugated equine estrogen therapies on domain-specific cognitive function: results from the Women's Health Initiative study of cognitive aging extension.The 2012 hormone therapy position statement of: The North American Menopause Society.Treatment-associated musculoskeletal and vasomotor symptoms and relapse-free survival in the NCIC CTG MA.27 adjuvant breast cancer aromatase inhibitor trial.Breast cancer after use of estrogen plus progestin in postmenopausal women.Vasomotor symptoms and cardiovascular events in postmenopausal women.Sleep problems after short-term hormone therapy suspension: secondary analysis of a randomized trial.Calcium and vitamin D supplementation do not influence menopause-related symptoms: Results of the Women's Health Initiative Trial.Changing concepts: Menopausal hormone therapy and breast cancer.Fat, fit, or famished? No clear answers from the Women's Health Initiative about diet and dieting for longstanding hot flashes Commentary: What's the deal with menopause management? Why the Women's Health Initiative raises more questions than it answers.Relapse of vasomotor symptoms after discontinuation of the selective serotonin reuptake inhibitor escitalopram: results from the menopause strategies: finding lasting answers for symptoms and health research network.Vitamin D levels and menopause-related symptoms.Health related quality of life after combined hormone replacement therapy: randomised controlled trial Care of the menopausal patient: a nurse practitioner's view.Aromatase inhibitors augment nociceptive behaviors in rats and enhance the excitability of sensory neurons.Impact of a soy drink on climacteric symptoms: an open-label, crossover, randomized clinical trial.Menopausal hormone therapy for vasomotor symptoms: balancing the risks and benefits with ultra-low doses of estrogen.Menopausal symptom experience before and after stopping estrogen therapy in the Women's Health Initiative randomized, placebo-controlled trial.Sex, gender, and pain: a review of recent clinical and experimental findings.Effects of L-isoleucine and L-valine on hot flushes and serum homocysteine: a randomized controlled trial.Continuous Combined Estrogen Plus Progestin and Endometrial Cancer: The Women's Health Initiative Randomized Trial.Safety and benefit considerations for menopausal hormone therapy.Depression during the menopause transition: impact on quality of life, social adjustment, and disability.Longitudinal changes in menopausal symptoms comparing women randomized to low-dose oral conjugated estrogens or transdermal estradiol plus micronized progesterone versus placebo: the Kronos Early Estrogen Prevention Study.Tapering versus cold turkey: symptoms versus successful discontinuation of menopausal hormone therapy.Pain symptoms during the menopausal transition and early postmenopause.Effect of abrupt discontinuation versus gradual dose reduction of postmenopausal hormone therapy on hot flushes.Progesterone for hot flush and night sweat treatment--effectiveness for severe vasomotor symptoms and lack of withdrawal rebound.No sweat: managing menopausal symptoms at work.Sexual activity and vaginal symptoms in the postintervention phase of the Women's Health Initiative Hormone Therapy Trials.Reliable evidence from placebo-controlled, randomized, clinical trials for menopausal hormone therapy's influence on incidence and deaths from breast cancer.Vasomotor Symptoms Across the Menopause Transition: Differences Among Women

P2860

Q24642671-FC2446DC-B618-4102-9101-27585E7F65D9 Q24658109-DAF7C284-3EF6-4377-8E4C-51725061E042 Q27022201-B226ECA4-7ED9-4506-8F38-FCD0D8183DB3 Q30448720-800DB820-B0FB-477E-AF49-ACE8EA941B7E Q33571609-9C1A9E50-AA55-49F9-BCFC-9167ECEF5416 Q34031251-2D2F540B-8A44-40CA-9534-1B8102F4B6B2 Q34048789-9C952A7D-B45D-419E-B970-89240DD8C6F6 Q34161400-589882AE-8F80-40CE-9608-9D0A569BE22F Q34903656-30ED4B00-AF56-4413-B081-032E6547D1AB Q34938322-E5D08BEB-8FC1-4ACC-85A4-01CAFE1020AE Q35068867-782485C7-C7EC-4DBC-9145-422BC6AFF496 Q35473768-24F18C00-4E80-4B1C-8830-EC769B94D6F6 Q35748587-A96F1548-80D6-4734-83C1-7E78D01959F8 Q35866374-C7255C41-D577-4E4D-AB04-291686E9AF83 Q36192728-20422C68-7B09-4C56-BD1A-19B001F4CDC7 Q36257886-1614815F-3C1F-40A2-8395-2DAC1E4D1DF5 Q36579331-0DA24B58-17E6-4F5A-9311-CCEAB22700B1 Q36608678-790174B3-52CB-4F48-88DB-BDD284ECF918 Q36843105-E7636129-F9D3-47BA-879D-B8C49D8103AD Q36892860-568F226C-114C-4995-9CA8-006EA10E0123 Q36927755-026D8F6A-07DC-4D2E-A7F8-EBDF3CDC44CD Q36981460-D3DC3732-CC39-43D4-8C26-5D4B5A62D6B9 Q37016116-C1572C49-9432-4011-8037-BF46189492AF Q37163204-8F274840-62CD-4795-ACD3-283AC30C8101 Q37180957-BA9EC0AA-B009-4CBC-9E2C-C4A5BDD4D197 Q37342803-0A0AF2DC-90F4-4F74-A29B-CFD72240DE9A Q37353846-92DF345C-8D47-47F6-B34A-EB4A4728C1FB Q38700757-4097AE5A-2549-4F7B-9E45-C596585F5714 Q38779937-D5B2063E-BD41-457C-AA0C-B128B519323B Q39165361-07001706-16E7-4BF5-BF15-3E9944347157 Q42578843-AF8BB8B0-515A-4860-9AFF-5C4F160435FB Q43055691-36948912-273E-4234-BBFB-9E09707D7143 Q43164033-0A5E9B23-4B29-439B-9243-60B1DB2ED085 Q44750448-A22CA196-76BA-43A7-BECB-AACC084CEE86 Q47320076-D1CD3F1D-EC80-48EC-B0FB-E9363F088237 Q50121638-10F49CC1-6807-4DE9-92AD-ED2F0655ABE0 Q50916380-411FC6E7-CDA0-45EF-A327-3E4C4047855B Q58551831-B2ACA69A-D667-495A-B4BC-BC16BA6522B7

P2860

Symptom experience after discontinuing use of estrogen plus progestin.

http://www.wikidata.org/entity/Q34433581

description

2005 nî lūn-bûn

@nan

2005 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2005 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

name

Symptom experience after discontinuing use of estrogen plus progestin.

@ast

Symptom experience after discontinuing use of estrogen plus progestin.

@en

Symptom experience after discontinuing use of estrogen plus progestin.

@nl

type

label

Symptom experience after discontinuing use of estrogen plus progestin.

@ast

Symptom experience after discontinuing use of estrogen plus progestin.

@en

Symptom experience after discontinuing use of estrogen plus progestin.

@nl

prefLabel

Symptom experience after discontinuing use of estrogen plus progestin.

@ast

Symptom experience after discontinuing use of estrogen plus progestin.

@en

Symptom experience after discontinuing use of estrogen plus progestin.

@nl

P1433

Q34433581-FBD4D74F-D0C0-47F5-A450-79155254F467

P1476

Q34433581-0B1BD25D-77CB-4AAD-AE23-57147AC3E4D2

P2093

Q34433581-2A269B40-5DC6-4CAA-BCC3-4538D4AC2FD3

Q34433581-2DF5E064-FBB2-46AB-A416-87EDB6E1BA0F

Q34433581-2EEED9B4-4EA7-4715-9F7F-9DDD097C574A

Q34433581-355BD004-827A-4F40-A68A-DDB78B570333

Q34433581-3C024B25-BD5D-4FD8-BF6C-D07B2A49EFA0

Q34433581-76BF2EA8-5D2E-4B66-B8F2-2218D791B939

Q34433581-8026564D-4076-4836-AC47-AD123E9A704E

Q34433581-A7CC982D-A077-4D0C-B170-967FDC56A21C

Q34433581-C0EC7E30-7987-4B53-9047-4DB87CB7DEB9

Q34433581-D5CB747E-A1FA-43D2-B469-958C79B2C2B7

P304

Q34433581-3E4FC55E-7E88-4EE3-AB74-1BD89723C75A

P31

Q34433581-D9741136-7EB6-4913-B24F-64184E772F3F

P356

Q34433581-DBB36486-FD0A-478E-9B74-AB2B32EB06A5

P407

Q34433581-08FB735E-34C1-4D04-9B1E-AF1E0908294E

P433

Q34433581-C019323A-BE53-40D0-9256-C95FAC7ED7E5

P478

Q34433581-DDD26E85-3ED2-44EC-876A-6FC66DB2B0F2

P50

Q34433581-FDC071EA-568D-4152-A602-0420523792FD

P577

Q34433581-D79DFD52-1D1E-47D7-994F-3AB5F61D2A69

P5875

Q34433581-06A70D0E-1385-49D4-AC37-00200E6F4704

P698

Q34433581-45D4FD85-DF55-4BF0-A471-769F1C0CD9FB

P356

P1433

Journal of the American Medical Association

P1476

Symptom experience after discontinuing use of estrogen plus progestin.

@en

P2093

Barbara B Cochrane

http://www.w3.org/2001/XMLSchema#string

David H Barad

http://www.w3.org/2001/XMLSchema#string

Dorothy S Lane

http://www.w3.org/2001/XMLSchema#string

Jennifer Hays

http://www.w3.org/2001/XMLSchema#string

JoAnn E Manson

http://www.w3.org/2001/XMLSchema#string

Joseph C Larson

http://www.w3.org/2001/XMLSchema#string

Judith K Ockene

http://www.w3.org/2001/XMLSchema#string

Judy Wylie-Rosett

http://www.w3.org/2001/XMLSchema#string

Margery Gass

http://www.w3.org/2001/XMLSchema#string

Milagros C Rosal

http://www.w3.org/2001/XMLSchema#string

P304

183-193

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1001/JAMA.294.2.183

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

294

http://www.w3.org/2001/XMLSchema#string

P50

Sylvia Wassertheil-Smoller

P577

2005-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7729265

http://www.w3.org/2001/XMLSchema#string

P698

16014592

http://www.w3.org/2001/XMLSchema#string